Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: A controlled trial

Elizabeth Berry-Kravis, Sue Ellen Krause, Sandra S. Block, Steve Guter, Joanne Wuu, Sue Leurgans, Penelope Decle, Kristina Potanos, Edwin Cook, Jeff Salt, Dominick Maino, Dahlia Weinberg, Rebecca Lara, Tristan Jardini, Jennifer Cogswell, Steven A. Johnson, Randi Hagerman

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

A Phase II, 4-week randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the safety and efficacy of the Ampakine compound CX516 as a potential treatment for the underlying disorder in fragile X syndrome (FXS). After baseline screening, subjects with FXS (n = 49) underwent a 1-week placebo lead-in and then were randomized to study drug or placebo for a 4-week period. Cognitive and behavioral outcome measures were administered prior to treatment, at the end of treatment, and 2 weeks posttreatment. There were minimal side effects, no significant changes in safety parameters, and no serious adverse events. There was a 12.5% frequency of allergic rash in the CX516 group and 1 subject developed a substantial rash. There was also no significant improvement in memory, the pri-mary outcome measure, or in secondary measures of language, attention/executive function, behavior, and overall functioning in CX516-treated subjects compared to placebo. This study did demonstrate that many outcome measures were reproducible in this test-retest setting for the FXS population, yet some were too difficult or variable. Adult subjects with FXS were able to complete an intensive clinical trial, and some valid outcome measures were identified for future FXS trial design. Problems with potency of CX516 in other studies have suggested dosing may have been inadequate for therapeutic effect and thus it remains unclear whether modulation of AMPA-mediated neurotransmission is a viable therapeutic strategy for the treatment of FXS.

Original languageEnglish
Pages (from-to)525-540
Number of pages16
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number5
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Fragile X Syndrome
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Cognition
Placebos
Outcome Assessment (Health Care)
Exanthema
Therapeutics
Safety
Executive Function
Controlled Clinical Trials
Therapeutic Uses
Synaptic Transmission
1-(quinoxalin-6-ylcarbonyl)piperidine
Language
Clinical Trials
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome : A controlled trial. / Berry-Kravis, Elizabeth; Krause, Sue Ellen; Block, Sandra S.; Guter, Steve; Wuu, Joanne; Leurgans, Sue; Decle, Penelope; Potanos, Kristina; Cook, Edwin; Salt, Jeff; Maino, Dominick; Weinberg, Dahlia; Lara, Rebecca; Jardini, Tristan; Cogswell, Jennifer; Johnson, Steven A.; Hagerman, Randi.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 5, 01.10.2006, p. 525-540.

Research output: Contribution to journalArticle

Berry-Kravis, E, Krause, SE, Block, SS, Guter, S, Wuu, J, Leurgans, S, Decle, P, Potanos, K, Cook, E, Salt, J, Maino, D, Weinberg, D, Lara, R, Jardini, T, Cogswell, J, Johnson, SA & Hagerman, R 2006, 'Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: A controlled trial', Journal of Child and Adolescent Psychopharmacology, vol. 16, no. 5, pp. 525-540. https://doi.org/10.1089/cap.2006.16.525
Berry-Kravis, Elizabeth ; Krause, Sue Ellen ; Block, Sandra S. ; Guter, Steve ; Wuu, Joanne ; Leurgans, Sue ; Decle, Penelope ; Potanos, Kristina ; Cook, Edwin ; Salt, Jeff ; Maino, Dominick ; Weinberg, Dahlia ; Lara, Rebecca ; Jardini, Tristan ; Cogswell, Jennifer ; Johnson, Steven A. ; Hagerman, Randi. / Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome : A controlled trial. In: Journal of Child and Adolescent Psychopharmacology. 2006 ; Vol. 16, No. 5. pp. 525-540.
@article{edfa6998b4f44230a1f5c84ae8f0086b,
title = "Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: A controlled trial",
abstract = "A Phase II, 4-week randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the safety and efficacy of the Ampakine compound CX516 as a potential treatment for the underlying disorder in fragile X syndrome (FXS). After baseline screening, subjects with FXS (n = 49) underwent a 1-week placebo lead-in and then were randomized to study drug or placebo for a 4-week period. Cognitive and behavioral outcome measures were administered prior to treatment, at the end of treatment, and 2 weeks posttreatment. There were minimal side effects, no significant changes in safety parameters, and no serious adverse events. There was a 12.5{\%} frequency of allergic rash in the CX516 group and 1 subject developed a substantial rash. There was also no significant improvement in memory, the pri-mary outcome measure, or in secondary measures of language, attention/executive function, behavior, and overall functioning in CX516-treated subjects compared to placebo. This study did demonstrate that many outcome measures were reproducible in this test-retest setting for the FXS population, yet some were too difficult or variable. Adult subjects with FXS were able to complete an intensive clinical trial, and some valid outcome measures were identified for future FXS trial design. Problems with potency of CX516 in other studies have suggested dosing may have been inadequate for therapeutic effect and thus it remains unclear whether modulation of AMPA-mediated neurotransmission is a viable therapeutic strategy for the treatment of FXS.",
author = "Elizabeth Berry-Kravis and Krause, {Sue Ellen} and Block, {Sandra S.} and Steve Guter and Joanne Wuu and Sue Leurgans and Penelope Decle and Kristina Potanos and Edwin Cook and Jeff Salt and Dominick Maino and Dahlia Weinberg and Rebecca Lara and Tristan Jardini and Jennifer Cogswell and Johnson, {Steven A.} and Randi Hagerman",
year = "2006",
month = "10",
day = "1",
doi = "10.1089/cap.2006.16.525",
language = "English",
volume = "16",
pages = "525--540",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome

T2 - A controlled trial

AU - Berry-Kravis, Elizabeth

AU - Krause, Sue Ellen

AU - Block, Sandra S.

AU - Guter, Steve

AU - Wuu, Joanne

AU - Leurgans, Sue

AU - Decle, Penelope

AU - Potanos, Kristina

AU - Cook, Edwin

AU - Salt, Jeff

AU - Maino, Dominick

AU - Weinberg, Dahlia

AU - Lara, Rebecca

AU - Jardini, Tristan

AU - Cogswell, Jennifer

AU - Johnson, Steven A.

AU - Hagerman, Randi

PY - 2006/10/1

Y1 - 2006/10/1

N2 - A Phase II, 4-week randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the safety and efficacy of the Ampakine compound CX516 as a potential treatment for the underlying disorder in fragile X syndrome (FXS). After baseline screening, subjects with FXS (n = 49) underwent a 1-week placebo lead-in and then were randomized to study drug or placebo for a 4-week period. Cognitive and behavioral outcome measures were administered prior to treatment, at the end of treatment, and 2 weeks posttreatment. There were minimal side effects, no significant changes in safety parameters, and no serious adverse events. There was a 12.5% frequency of allergic rash in the CX516 group and 1 subject developed a substantial rash. There was also no significant improvement in memory, the pri-mary outcome measure, or in secondary measures of language, attention/executive function, behavior, and overall functioning in CX516-treated subjects compared to placebo. This study did demonstrate that many outcome measures were reproducible in this test-retest setting for the FXS population, yet some were too difficult or variable. Adult subjects with FXS were able to complete an intensive clinical trial, and some valid outcome measures were identified for future FXS trial design. Problems with potency of CX516 in other studies have suggested dosing may have been inadequate for therapeutic effect and thus it remains unclear whether modulation of AMPA-mediated neurotransmission is a viable therapeutic strategy for the treatment of FXS.

AB - A Phase II, 4-week randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the safety and efficacy of the Ampakine compound CX516 as a potential treatment for the underlying disorder in fragile X syndrome (FXS). After baseline screening, subjects with FXS (n = 49) underwent a 1-week placebo lead-in and then were randomized to study drug or placebo for a 4-week period. Cognitive and behavioral outcome measures were administered prior to treatment, at the end of treatment, and 2 weeks posttreatment. There were minimal side effects, no significant changes in safety parameters, and no serious adverse events. There was a 12.5% frequency of allergic rash in the CX516 group and 1 subject developed a substantial rash. There was also no significant improvement in memory, the pri-mary outcome measure, or in secondary measures of language, attention/executive function, behavior, and overall functioning in CX516-treated subjects compared to placebo. This study did demonstrate that many outcome measures were reproducible in this test-retest setting for the FXS population, yet some were too difficult or variable. Adult subjects with FXS were able to complete an intensive clinical trial, and some valid outcome measures were identified for future FXS trial design. Problems with potency of CX516 in other studies have suggested dosing may have been inadequate for therapeutic effect and thus it remains unclear whether modulation of AMPA-mediated neurotransmission is a viable therapeutic strategy for the treatment of FXS.

UR - http://www.scopus.com/inward/record.url?scp=33750962399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750962399&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.525

DO - 10.1089/cap.2006.16.525

M3 - Article

C2 - 17069542

AN - SCOPUS:33750962399

VL - 16

SP - 525

EP - 540

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 5

ER -